Insufficient scRNA-seq data for expression of EFNA2 at single-cell level.
Insufficient scRNA-seq data for expression of EFNA2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 267.88 | 226 / 226 | 87% | 8.60 | 355 / 406 |
brain | 98% | 41.58 | 2576 / 2642 | 90% | 8.47 | 634 / 705 |
intestine | 61% | 243.43 | 588 / 966 | 92% | 28.68 | 483 / 527 |
stomach | 8% | 0.91 | 28 / 359 | 88% | 25.36 | 251 / 286 |
pancreas | 5% | 0.59 | 17 / 328 | 77% | 11.93 | 137 / 178 |
esophagus | 30% | 6.32 | 431 / 1445 | 44% | 6.55 | 81 / 183 |
eye | 0% | 0 | 0 / 0 | 68% | 3.54 | 54 / 80 |
bladder | 24% | 3.29 | 5 / 21 | 42% | 8.64 | 211 / 504 |
kidney | 54% | 14.03 | 48 / 89 | 11% | 0.69 | 102 / 901 |
lung | 2% | 0.30 | 11 / 578 | 27% | 3.46 | 317 / 1155 |
ovary | 7% | 1.58 | 12 / 180 | 23% | 2.69 | 97 / 430 |
uterus | 6% | 0.86 | 10 / 170 | 22% | 2.43 | 100 / 459 |
prostate | 12% | 1.44 | 30 / 245 | 14% | 0.68 | 68 / 502 |
skin | 5% | 0.71 | 97 / 1809 | 17% | 1.08 | 79 / 472 |
muscle | 15% | 1.96 | 118 / 803 | 0% | 0 | 0 / 0 |
adrenal gland | 2% | 0.70 | 6 / 258 | 12% | 1.76 | 27 / 230 |
breast | 2% | 1.77 | 8 / 459 | 8% | 0.43 | 94 / 1118 |
blood vessel | 6% | 0.57 | 81 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 4% | 0.45 | 34 / 929 | 0% | 0 | 0 / 0 |
thymus | 3% | 0.42 | 19 / 653 | 0% | 0.04 | 3 / 605 |
adipose | 3% | 0.32 | 37 / 1204 | 0% | 0 | 0 / 0 |
heart | 2% | 0.28 | 21 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 2% | 0.06 | 1 / 45 |
spleen | 2% | 0.51 | 5 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0048013 | Biological process | ephrin receptor signaling pathway |
GO_0046849 | Biological process | bone remodeling |
GO_0030316 | Biological process | osteoclast differentiation |
GO_0021772 | Biological process | olfactory bulb development |
GO_0007267 | Biological process | cell-cell signaling |
GO_0007411 | Biological process | axon guidance |
GO_0043204 | Cellular component | perikaryon |
GO_0098552 | Cellular component | side of membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0031594 | Cellular component | neuromuscular junction |
GO_0005515 | Molecular function | protein binding |
GO_0046875 | Molecular function | ephrin receptor binding |
Gene name | EFNA2 |
Protein name | Ephrin-A2 (EPH-related receptor tyrosine kinase ligand 6) (LERK-6) (HEK7 ligand) (HEK7-L) Ephrin-A2 [amino acids 176-213] |
Synonyms | LERK6 EPLG6 |
Description | FUNCTION: Cell surface GPI-bound ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. Binds promiscuously Eph receptors residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. With the EPHA2 receptor may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis (By similarity). . |
Accessions | O43921 Q9HCB5 ENST00000215368.4 |